The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Logistic regression analysis showed that only AHI was a predictor of daytime hypercapnia ... daytime hypercapnia may be directly linked to sleep apnea in a subgroup of patients with OSAS.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

Try a single issue or save on a subscription Issues delivered straight to your door or device ...

CR shares expert guidance on the best sleep position, pillows, mattresses, and more if you have sleep apnea, GERD, asthma, ...

Apple this month received approval to launch the Apple Watch's sleep apnea notifications feature in Malaysia, as noted by ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Obstructive sleep apnea (OSA) is associated with an increased risk for cardiovascular disease (CVD) in adults, even those younger than 40 years, according to a study published online June 6 in the ...

or for physician-prescribed home testing for sleep apnea. Machine learning paired with some consumer-grade and newer professional-grade devices can extract patterns from the data, and holds ...